Develops an antibody therapy for severe low blood sugar caused by overactive insulin signaling, including congenital and tumor-related forms.
10-K for FY2026, filed Sep 24, 2026Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat…View ↗
Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.View ↗
Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in…View ↗
Ersodetug for Tumor HIView ↗
Tumor HI may be caused by two distinct types of solid tumors: neuroendocrine islet cell tumors (“ICTs”) and non-islet cell tumors…View ↗
No revenue reported yet.
10-K, filed Oct 13, 2020
10-Q for Q1 FY2027, filed Nov 5, 2026
−$18.5MView ↗
8-K, filed Nov 13, 2026
The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in…View ↗
8-K, filed Oct 5, 2026
REDWOOD CITY, Calif., October 5, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease…View ↗
A narrower disease focus
The earlier report described a therapy for congenital hyperinsulinism and an oral therapy for diabetic macular edema; the latest focuses on ersodetug for congenital and tumor-related hyperinsulinism.
10-K for FY2023, filed Sep 14, 2023 10-K for FY2026, filed Sep 24, 2026Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat…View ↗
Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.View ↗
Ersodetug for Tumor HIView ↗
Competes with Amylyx Pharmaceuticals, Hanmi Pharmaceuticals, and Zealand Pharma
10-K for FY2026, filed Sep 24, 2026There are other companies developing therapies for HI that are potential competitors to ersodetug, including, Amylyx Pharmaceuticals, Hanmi…View ↗
Loading...